Division of Takeda Pharmaceutical Co. Ltd.
Latest From TiGenix NV
New approvals in the EU were again dominated by oncology drugs in 2018, although medicines for infectious diseases were a close second. The number of orphan drugs more than doubled over the previous year, to 17. There were also some star arrivals in multiple sclerosis, genetic disorders, metabolism and migraine.
Executive Interview: A raft of clinical trial results are expected in the second half of 2018 for Bone Therapeutics' regenerative cell therapy approach to hip osteonecrosis and delayed-union fractures.
This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.
Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Drug Discovery Tools
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- Western Europe
- Parent & Subsidiaries
- Takeda Pharmaceutical Co. Ltd.
- Senior Management
Eduardo Bravo, Mng. Dir. & CEO
Claudia D’Augusta, CFO
Wilfried Dalemans, CTO
Marie Paule Richard, MD, CMO
- Contact Info
Phone: (32) 16 39 60 60
Romeinse Straat 12, Bus 2
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.